Merck KGaA CEO Belén Garijo at the company's press conference on March 7, 2024 (Arne Dedert/picture alliance via Getty Images)
Merck KGaA to focus on ‘external innovation’ as it exits BTK inhibitor race
Merck KGaA is revamping its R&D efforts as it increases focus on licensing deals rather than its internal pipeline. Several months after a Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.